$KAYS
Kaya Holdings, Inc. Stock $kays

$kays Overview Financials Valuation SEC Filings Company Website

2024 Q4 Form 10-Q Financial Statement

#000190359624000689 Filed on November 22, 2024

Income Statement

Concept	2024 Q4	2024 Q3	2023 Q3
Revenue		$3.000K	$59.01K
YoY Change		-94.92%	-65.88%
Cost Of Revenue		$272.00	$22.09K
YoY Change		-98.77%	-63.05%
Gross Profit		$2.728K	$36.92K
YoY Change		-92.61%	-67.38%
Gross Profit Margin		90.93%	62.57%
Selling, General & Admin			$310.0K
YoY Change			-19.07%
% of Gross Profit			839.59%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization			$0.00
YoY Change			-100.0%
% of Gross Profit			0.0%
Operating Expenses		$1.143M	$313.1K
YoY Change		265.15%	-18.28%
Operating Profit		-$1.140M	-$276.1K
YoY Change		312.99%	2.32%
Interest Expense			$2.070M
YoY Change			-128.91%
% of Operating Profit
Other Income/Expense, Net		-$1.355M	$2.377M
YoY Change		-157.0%	-133.28%
Pretax Income		-$2.495M	$2.101M
YoY Change		-218.77%	-128.34%
Income Tax			$5.270K
% Of Pretax Income			0.25%
Net Earnings		-$2.457M	$2.096M
YoY Change		-217.24%	-128.26%
Net Earnings / Revenue		-81903.03%	3551.44%
Basic Earnings Per Share		-$0.10	$0.09
Diluted Earnings Per Share		-$0.10	$0.09
COMMON SHARES
Basic Shares Outstanding	41.57M shares	24.33M shares	22.17M shares
Diluted Shares Outstanding		24.33M shares	143.7M shares

Balance Sheet

Concept	2024 Q3	2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments		$60.00K
YoY Change		48.48%
Cash & Equivalents	$64.79K	$60.27K
Short-Term Investments
Other Short-Term Assets		$50.00K
YoY Change		257.91%
Inventory	$240.00	$13.26K
Prepaid Expenses	$26.55K	$49.76K
Receivables
Other Receivables
Total Short-Term Assets	$91.58K	$123.3K
YoY Change	-25.71%	48.38%
LONG-TERM ASSETS
Property, Plant & Equipment	$40.26K	$26.79K
YoY Change	50.31%	-95.19%
Goodwill	$24.04K
YoY Change
Intangibles
YoY Change
Long-Term Investments		$20.00K
YoY Change		-9.71%
Other Assets	$29.55K	$40.01K
YoY Change	-26.13%	-56.38%
Total Long-Term Assets	$177.0K	$107.3K
YoY Change	65.02%	-87.79%
TOTAL ASSETS
Total Short-Term Assets	$91.58K	$123.3K
Total Long-Term Assets	$177.0K	$107.3K
Total Assets	$268.6K	$230.6K
YoY Change	16.5%	-76.02%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable		$1.020M
YoY Change		587.54%
Accrued Expenses		$2.210M
YoY Change		31.14%
Deferred Revenue
YoY Change
Short-Term Debt		$110.0K
YoY Change		1081.53%
Long-Term Debt Due		$109.3K
YoY Change		17.11%
Total Short-Term Liabilities	$9.091M	$7.771M
YoY Change	16.98%	-39.66%
LONG-TERM LIABILITIES
Long-Term Debt		$7.950M
YoY Change		8.61%
Other Long-Term Liabilities		$500.0K
YoY Change		-21.37%
Total Long-Term Liabilities	$9.339M	$8.448M
YoY Change	10.55%	6.18%
TOTAL LIABILITIES
Total Short-Term Liabilities	$9.091M	$7.771M
Total Long-Term Liabilities	$9.339M	$8.448M
Total Liabilities	$18.43M	$16.22M
YoY Change	13.63%	-22.15%
SHAREHOLDERS EQUITY
Retained Earnings	-$39.60M	-$36.70M
YoY Change	7.9%	-7.97%
Common Stock	$4.157K	$22.17K
YoY Change	-81.25%	50.6%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$16.10M	-$15.99M
YoY Change
Total Liabilities & Shareholders Equity	$268.6K	$230.6K
YoY Change	16.5%	-76.02%

Cashflow Statement

Concept	2024 Q3	2023 Q3
OPERATING ACTIVITIES
Net Income	-$2.457M	$2.096M
YoY Change	-217.24%	-128.26%
Depreciation, Depletion And Amortization		$0.00
YoY Change		-100.0%
Cash From Operating Activities		-$170.0K
YoY Change		-1.95%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities		$0.00
YoY Change		-100.0%
Cash From Investing Activities		$0.00
YoY Change		-100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities		110.0K
YoY Change		-26.67%
NET CHANGE
Cash From Operating Activities		-170.0K
Cash From Investing Activities		0.000
Cash From Financing Activities		110.0K
Net Change In Cash		-60.00K
YoY Change		867.74%
FREE CASH FLOW
Cash From Operating Activities		-$170.0K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	333-177532
	dei	Entity Registrant Name EntityRegistrantName	KAYA HOLDINGS, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Address Address Line1 EntityAddressAddressLine1	915 Middle River Drive
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 316
	dei	Entity Address State Or Province EntityAddressStateOrProvince	FL
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	33304
	dei	City Area Code CityAreaCode	954
	dei	Local Phone Number LocalPhoneNumber	892-6911
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	us-gaap	Salaries Wages And Officers Compensation SalariesWagesAndOfficersCompensation	140871	usd
CY2024Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	291444	usd
CY2023Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	97916	usd
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
	dei	Entity Central Index Key EntityCentralIndexKey	0001530746
CY2024Q3	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2024Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
CY2023Q3	us-gaap	Gain Loss On Sale Of Other Assets GainLossOnSaleOfOtherAssets		usd
CY2024Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense		usd
CY2024Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
	KAYS	Shares Issued For Services SharesIssuedForServices		usd
	KAYS	Shares Issued For Services Related Parties SharesIssuedForServicesRelatedParties		usd
	KAYS	Shares Issued For Acquisition Related Parties SharesIssuedForAcquisitionRelatedParties		usd
	us-gaap	Gain Loss On Disposition Of Intangible Assets GainLossOnDispositionOfIntangibleAssets		usd
	us-gaap	Gains Losses On Restructuring Of Debt GainsLossesOnRestructuringOfDebt		usd
	us-gaap	Increase Decrease In Deposit Other Assets IncreaseDecreaseInDepositOtherAssets		usd
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets		usd
	us-gaap	Proceeds From Sale Of Intangible Assets ProceedsFromSaleOfIntangibleAssets		usd
	us-gaap	Proceeds From Sale Of Other Productive Assets ProceedsFromSaleOfOtherProductiveAssets		usd
	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities		usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment		usd
	us-gaap	Proceeds From Sale Of Other Assets Investing Activities ProceedsFromSaleOfOtherAssetsInvestingActivities		usd
	us-gaap	Settlement Of Asset Retirement Obligations Through Noncash Payments Amount SettlementOfAssetRetirementObligationsThroughNoncashPaymentsAmount		usd
	us-gaap	Transfer Of Other Real Estate TransferOfOtherRealEstate		usd
	us-gaap	Liabilities Assumed1 LiabilitiesAssumed1		usd
	us-gaap	Transfer Of Portfolio Loans And Leases To Held For Sale1 TransferOfPortfolioLoansAndLeasesToHeldForSale1		usd
	us-gaap	Contribution Of Property ContributionOfProperty		usd
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2024-09-30
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	90-0898007
	dei	Entity Address City Or Town EntityAddressCityOrTown	Ft. Lauderdale
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2024Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	41572835	shares
CY2024Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	64794	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	29108	usd
CY2024Q3	us-gaap	Inventory Net InventoryNet	240	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	9259	usd
CY2024Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	26549	usd
CY2023Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	58588	usd
CY2024Q3	us-gaap	Assets Current AssetsCurrent	91583	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	96955	usd
CY2024Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	83155	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	29865	usd
CY2024Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	220270	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	216890	usd
CY2024Q3	us-gaap	Property Plant And Equipment Other Net PropertyPlantAndEquipmentOtherNet	40261	usd
CY2023Q4	us-gaap	Property Plant And Equipment Other Net PropertyPlantAndEquipmentOtherNet	24875	usd
CY2024Q3	us-gaap	Goodwill Goodwill	24037	usd
CY2023Q4	us-gaap	Goodwill Goodwill	23682	usd
CY2024Q3	us-gaap	Other Assets OtherAssets	29553	usd
CY2023Q4	us-gaap	Other Assets OtherAssets	40479	usd
CY2024Q3	us-gaap	Assets Noncurrent AssetsNoncurrent	177006	usd
CY2023Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	118901	usd
CY2024Q3	us-gaap	Assets Assets	268589	usd
CY2023Q4	us-gaap	Assets Assets	215856	usd
CY2024Q3	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	646100	usd
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	589085	usd
CY2024Q3	us-gaap	Accounts Payable And Accrued Liabilities Fair Value Disclosure AccountsPayableAndAccruedLiabilitiesFairValueDisclosure	754557	usd
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Fair Value Disclosure AccountsPayableAndAccruedLiabilitiesFairValueDisclosure	514972	usd
CY2024Q3	us-gaap	Interest Payable Current InterestPayableCurrent	2659752	usd
CY2023Q4	us-gaap	Interest Payable Current InterestPayableCurrent	2369015	usd
CY2024Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	83155	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	30885	usd
CY2024Q3	us-gaap	Taxes Payable Current TaxesPayableCurrent	902163	usd
CY2023Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	899344	usd
CY2024Q3	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	0	usd
CY2023Q4	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	0	usd
CY2024Q3	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	135000	usd
CY2023Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	125000	usd
CY2024Q3	us-gaap	Other Notes Payable Current OtherNotesPayableCurrent	9312	usd
CY2023Q4	us-gaap	Other Notes Payable Current OtherNotesPayableCurrent	124312	usd
CY2024Q3	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	3900734	usd
CY2023Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	2752321	usd
CY2024Q3	us-gaap	Liabilities Current LiabilitiesCurrent	9090773	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	7404934	usd
CY2024Q3	us-gaap	Senior Long Term Notes SeniorLongTermNotes	500000	usd
CY2023Q4	us-gaap	Senior Long Term Notes SeniorLongTermNotes	500000	usd
CY2024Q3	us-gaap	Other Long Term Notes Payable OtherLongTermNotesPayable	250000	usd
CY2023Q4	us-gaap	Other Long Term Notes Payable OtherLongTermNotesPayable	250000	usd
CY2024Q3	KAYS	Convertible Notes Payable Net Of Discount Non Current ConvertibleNotesPayableNetOfDiscountNonCurrent	294368	usd
CY2023Q4	KAYS	Convertible Notes Payable Net Of Discount Non Current ConvertibleNotesPayableNetOfDiscountNonCurrent	742	usd
CY2024Q3	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	8088952	usd
CY2023Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	7311410	usd
CY2024Q3	us-gaap	Accounts Payable And Accrued Liabilities Noncurrent AccountsPayableAndAccruedLiabilitiesNoncurrent	500000	usd
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Noncurrent AccountsPayableAndAccruedLiabilitiesNoncurrent	500000	usd
CY2024Q3	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	9338952	usd
CY2023Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	8561410	usd
CY2024Q3	us-gaap	Liabilities Liabilities	18429725	usd
CY2023Q4	us-gaap	Liabilities Liabilities	15966344	usd
CY2024Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2024Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1500000000	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1500000000	shares
CY2024Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	41572835	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	22172835	shares
CY2024Q3	us-gaap	Common Stock Value CommonStockValue	4157	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	2217	usd
CY2024Q3	us-gaap	Preferred Stock Shares Subscribed But Unissued Value PreferredStockSharesSubscribedButUnissuedValue	163630	usd
CY2023Q4	us-gaap	Preferred Stock Shares Subscribed But Unissued Value PreferredStockSharesSubscribedButUnissuedValue	163630	usd
CY2024Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	23344739	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	22513739	usd
CY2024Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-39601954	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-36462263	usd
CY2024Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-12108	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-12617	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	-16101536	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-13795294	usd
CY2024Q3	us-gaap	Minority Interest MinorityInterest	-2059600	usd
CY2023Q4	us-gaap	Minority Interest MinorityInterest	-1955194	usd
CY2024Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-18161136	usd
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-15750488	usd
CY2024Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	268589	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	215856	usd
CY2024Q3	us-gaap	Revenues Revenues	3000	usd
CY2023Q3	us-gaap	Revenues Revenues	59011	usd
	us-gaap	Revenues Revenues	31009	usd
	us-gaap	Revenues Revenues	162372	usd
CY2024Q3	us-gaap	Cost Of Revenue CostOfRevenue	272	usd
CY2023Q3	us-gaap	Cost Of Revenue CostOfRevenue	22088	usd
	us-gaap	Cost Of Revenue CostOfRevenue	13678	usd
	us-gaap	Cost Of Revenue CostOfRevenue	58402	usd
CY2024Q3	us-gaap	Gross Profit GrossProfit	2728	usd
CY2023Q3	us-gaap	Gross Profit GrossProfit	36923	usd
	us-gaap	Gross Profit GrossProfit	17331	usd
	us-gaap	Gross Profit GrossProfit	103970	usd
CY2024Q3	us-gaap	Professional Fees ProfessionalFees	813829	usd
CY2023Q3	us-gaap	Professional Fees ProfessionalFees	170405	usd
	us-gaap	Professional Fees ProfessionalFees	1173601	usd
	us-gaap	Professional Fees ProfessionalFees	563670	usd
CY2024Q3	us-gaap	Salaries Wages And Officers Compensation SalariesWagesAndOfficersCompensation	37851	usd
CY2023Q3	us-gaap	Salaries Wages And Officers Compensation SalariesWagesAndOfficersCompensation	44732	usd
	us-gaap	Salaries Wages And Officers Compensation SalariesWagesAndOfficersCompensation	126934	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	555014	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	324750	usd
CY2024Q3	us-gaap	Operating Expenses OperatingExpenses	1143124	usd
CY2023Q3	us-gaap	Operating Expenses OperatingExpenses	313053	usd
	us-gaap	Operating Expenses OperatingExpenses	1855549	usd
	us-gaap	Operating Expenses OperatingExpenses	1029291	usd
CY2024Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-1140396	usd
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-276130	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-1838218	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-925321	usd
CY2024Q3	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	189726	usd
CY2023Q3	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	165774	usd
	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	539619	usd
	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	484106	usd
CY2024Q3	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	82040	usd
CY2023Q3	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	68762	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	108835	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	318315	usd
CY2023Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	219006	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	151082	usd
CY2024Q3	us-gaap	Gain Loss On Sale Of Other Assets GainLossOnSaleOfOtherAssets	1700	usd
	us-gaap	Gain Loss On Sale Of Other Assets GainLossOnSaleOfOtherAssets	1700	usd
	us-gaap	Gain Loss On Sale Of Other Assets GainLossOnSaleOfOtherAssets	384429	usd
CY2024Q3	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Gain Loss Included In Other Comprehensive Income Loss FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInOtherComprehensiveIncomeLoss	-1084865	usd
CY2023Q3	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Gain Loss Included In Other Comprehensive Income Loss FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInOtherComprehensiveIncomeLoss	2302249	usd
	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Gain Loss Included In Other Comprehensive Income Loss FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInOtherComprehensiveIncomeLoss	-759620	usd
	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Gain Loss Included In Other Comprehensive Income Loss FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInOtherComprehensiveIncomeLoss	2535936	usd
CY2023Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	90423	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	3614	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	91923	usd
CY2024Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1354931	usd
CY2023Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	2377142	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1402760	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	2360949	usd
CY2024Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-2495327	usd
CY2023Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	2101012	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-3240978	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	1435628	usd
CY2023Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	5270	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2819	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	19109	usd
CY2024Q3	us-gaap	Profit Loss ProfitLoss	-2495327	usd
CY2023Q3	us-gaap	Profit Loss ProfitLoss	2095742	usd
	us-gaap	Profit Loss ProfitLoss	-3243797	usd
	us-gaap	Profit Loss ProfitLoss	1416519	usd
CY2024Q3	us-gaap	Net Income Loss From Real Estate Investment Partnership Attributable To Noncontrolling Interest NetIncomeLossFromRealEstateInvestmentPartnershipAttributableToNoncontrollingInterest	-38236	usd
CY2023Q3	us-gaap	Net Income Loss From Real Estate Investment Partnership Attributable To Noncontrolling Interest NetIncomeLossFromRealEstateInvestmentPartnershipAttributableToNoncontrollingInterest	62117	usd
	us-gaap	Net Income Loss From Real Estate Investment Partnership Attributable To Noncontrolling Interest NetIncomeLossFromRealEstateInvestmentPartnershipAttributableToNoncontrollingInterest	-104106	usd
	us-gaap	Net Income Loss From Real Estate Investment Partnership Attributable To Noncontrolling Interest NetIncomeLossFromRealEstateInvestmentPartnershipAttributableToNoncontrollingInterest	48503	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-2457091	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	2033625	usd
	us-gaap	Net Income Loss NetIncomeLoss	-3139691	usd
	us-gaap	Net Income Loss NetIncomeLoss	1368016	usd
CY2024Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.10
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.09
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.13
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.06
CY2024Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	24327183	shares
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	22172835	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	23626850	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	22172835	shares
CY2024Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.10
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.01
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.13
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.01
CY2024Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	24327183	shares
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	143718093	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	23626850	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	143718093	shares
CY2024Q3	KAYS	Net Income Losss NetIncomeLosss	-2495327	usd
CY2023Q3	KAYS	Net Income Losss NetIncomeLosss	2033625	usd
	KAYS	Net Income Losss NetIncomeLosss	-3243797	usd
	KAYS	Net Income Losss NetIncomeLosss	1368016	usd
CY2024Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Before Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent	2210	usd
CY2023Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Before Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent	-2655	usd
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Before Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent	210	usd
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Before Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent	-1692	usd
CY2024Q3	KAYS	Other Comprehensive Income Loss Before Taxes Portion Attributable To Parent OtherComprehensiveIncomeLossBeforeTaxesPortionAttributableToParent	-2493117	usd
CY2023Q3	KAYS	Other Comprehensive Income Loss Before Taxes Portion Attributable To Parent OtherComprehensiveIncomeLossBeforeTaxesPortionAttributableToParent	2030970	usd
	KAYS	Other Comprehensive Income Loss Before Taxes Portion Attributable To Parent OtherComprehensiveIncomeLossBeforeTaxesPortionAttributableToParent	-3243587	usd
	KAYS	Other Comprehensive Income Loss Before Taxes Portion Attributable To Parent OtherComprehensiveIncomeLossBeforeTaxesPortionAttributableToParent	1366324	usd
CY2024Q3	us-gaap	Oci Equity Method Investment Tax Parent OciEquityMethodInvestmentTaxParent	-38236	usd
CY2023Q3	us-gaap	Oci Equity Method Investment Tax Parent OciEquityMethodInvestmentTaxParent	62117	usd
	us-gaap	Oci Equity Method Investment Tax Parent OciEquityMethodInvestmentTaxParent	-104106	usd
	us-gaap	Oci Equity Method Investment Tax Parent OciEquityMethodInvestmentTaxParent	48503	usd
CY2024Q3	us-gaap	Other Comprehensive Income Loss Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeLossTaxPortionAttributableToNoncontrollingInterest	-2454881	usd
CY2023Q3	us-gaap	Other Comprehensive Income Loss Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeLossTaxPortionAttributableToNoncontrollingInterest	1968853	usd
	us-gaap	Other Comprehensive Income Loss Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeLossTaxPortionAttributableToNoncontrollingInterest	-3139481	usd
	us-gaap	Other Comprehensive Income Loss Tax Portion Attributable To Noncontrolling Interest OtherComprehensiveIncomeLossTaxPortionAttributableToNoncontrollingInterest	1317821	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-3139691	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	1368016	usd
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Noncontrolling Interest IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest	-104106	usd
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Noncontrolling Interest IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest	48503	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	3380	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	9935	usd
	us-gaap	Paid In Kind Interest PaidInKindInterest	16890	usd
	us-gaap	Paid In Kind Interest PaidInKindInterest	16829	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	151082	usd
	KAYS	Shares Issued For Services SharesIssuedForServices	127100	usd
	KAYS	Shares Issued For Services Related Parties SharesIssuedForServicesRelatedParties	627300	usd
	KAYS	Shares Issued For Acquisition Related Parties SharesIssuedForAcquisitionRelatedParties	-41000	usd
	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Change In Unrealized Gain Loss FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss	-759620	usd
	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Change In Unrealized Gain Loss FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss	2535936	usd
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	108835	usd
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	318315	usd
	us-gaap	Gain Loss On Disposition Of Intangible Assets GainLossOnDispositionOfIntangibleAssets	384429	usd
	us-gaap	Gains Losses On Restructuring Of Debt GainsLossesOnRestructuringOfDebt	91923	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-32283	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	33963	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-9019	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-2145	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	88940	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	45499	usd
	us-gaap	Increase Decrease In Deposit Other Assets IncreaseDecreaseInDepositOtherAssets	12925	usd
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-11016	usd
	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	485737	usd
	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	433696	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	57015	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	14617	usd
	us-gaap	Increase Decrease In Accounts Payable Related Parties IncreaseDecreaseInAccountsPayableRelatedParties	239585	usd
	us-gaap	Increase Decrease In Accounts Payable Related Parties IncreaseDecreaseInAccountsPayableRelatedParties	144587	usd
	us-gaap	Increase Decrease In Other Operating Capital Net IncreaseDecreaseInOtherOperatingCapitalNet	89960	usd
	us-gaap	Increase Decrease In Other Operating Capital Net IncreaseDecreaseInOtherOperatingCapitalNet	47322	usd
	us-gaap	Increase Decrease In Income Taxes IncreaseDecreaseInIncomeTaxes	2819	usd
	us-gaap	Increase Decrease In Income Taxes IncreaseDecreaseInIncomeTaxes	4045	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-723218	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-855683	usd
	us-gaap	Proceeds From Sale Of Intangible Assets ProceedsFromSaleOfIntangibleAssets	693959	usd
	us-gaap	Proceeds From Sale Of Other Productive Assets ProceedsFromSaleOfOtherProductiveAssets	193900	usd
	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	75000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	18766	usd
	us-gaap	Proceeds From Sale Of Other Assets Investing Activities ProceedsFromSaleOfOtherAssetsInvestingActivities	20650	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	1884	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	812859	usd
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	872500	usd
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	455000	usd
	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	115000	usd
	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	370000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	757500	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	85000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	36166	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	42176	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-480	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-238	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	29108	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	18330	usd
CY2024Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	64794	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	60268	usd
	us-gaap	Interest Paid Net InterestPaidNet	10000	usd
	us-gaap	Interest Paid Net InterestPaidNet	28582	usd
	us-gaap	Settlement Of Asset Retirement Obligations Through Noncash Payments Amount SettlementOfAssetRetirementObligationsThroughNoncashPaymentsAmount	145625	usd
	us-gaap	Transfer Of Other Real Estate TransferOfOtherRealEstate	38329	usd
	us-gaap	Liabilities Assumed1 LiabilitiesAssumed1	388793	usd
	us-gaap	Transfer Of Portfolio Loans And Leases To Held For Sale1 TransferOfPortfolioLoansAndLeasesToHeldForSale1	142230	usd
	us-gaap	Contribution Of Property ContributionOfProperty	195000	usd
CY2024Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-16477089	usd
CY2024Q3	us-gaap	Stockholders Equity Other StockholdersEquityOther	5671	usd
CY2024Q3	us-gaap	Sale Of Stock Consideration Received Per Transaction SaleOfStockConsiderationReceivedPerTransaction	8000	usd
CY2024Q3	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	127100	usd
CY2024Q3	KAYS	Common Stock Issued For Services Related Parties CommonStockIssuedForServicesRelatedParties	627300	usd
CY2024Q3	KAYS	Commen Stock Issued For Acquiring Subsidiary CommenStockIssuedForAcquiringSubsidiary	41000	usd
CY2024Q3	us-gaap	Temporary Equity Foreign Currency Translation Adjustments TemporaryEquityForeignCurrencyTranslationAdjustments	2209	usd
CY2024Q3	us-gaap	Profit Loss ProfitLoss	-2495327	usd
CY2024Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-18161136	usd
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-15750488	usd
	us-gaap	Stockholders Equity Other StockholdersEquityOther	16890	usd
	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	127100	usd
	KAYS	Common Stock Issued For Services Related Parties CommonStockIssuedForServicesRelatedParties	627300	usd
	KAYS	Commen Stock Issued For Acquiring Subsidiary CommenStockIssuedForAcquiringSubsidiary	41000	usd
	us-gaap	Sale Of Stock Consideration Received Per Transaction SaleOfStockConsiderationReceivedPerTransaction	20650	usd
	us-gaap	Temporary Equity Foreign Currency Translation Adjustments TemporaryEquityForeignCurrencyTranslationAdjustments	209	usd
	us-gaap	Profit Loss ProfitLoss	-3243797	usd
CY2024Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-18161136	usd
CY2023Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-18125218	usd
CY2023Q3	us-gaap	Stockholders Equity Other StockholdersEquityOther	5671	usd
CY2023Q3	us-gaap	Temporary Equity Foreign Currency Translation Adjustments TemporaryEquityForeignCurrencyTranslationAdjustments	-2655	usd
CY2023Q3	us-gaap	Profit Loss ProfitLoss	2095742	usd
CY2023Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-15988131	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-17603741	usd
	us-gaap	Stockholders Equity Other StockholdersEquityOther	16829	usd
	KAYS	Settlement Of Derivative Liabilities To Additional Paid In Capital SettlementOfDerivativeLiabilitiesToAdditionalPaidInCapital	145625	usd
	us-gaap	Temporary Equity Foreign Currency Translation Adjustments TemporaryEquityForeignCurrencyTranslationAdjustments	-1692	usd
	us-gaap	Profit Loss ProfitLoss	1416519	usd
CY2023Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-15988131	usd
	us-gaap	Nature Of Operations NatureOfOperations	<p id="xdx_803_eus-gaap--NatureOfOperations_z9rUjosfWGlh" style="margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 1 –<span id="xdx_829_z86wbfVBYLx8"> ORGANIZATION AND NATURE OF THE BUSINESS</span></b></span></p> <p style="margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Organization</b></span></p> <p style="margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kaya Holdings, Inc. FKA (Alternative Fuels Americas, Inc.) is a holding company. The Company was incorporated in 1993 and engaged in a number of businesses until September, 2010. In October, 2010, the Company changed its name to Alternative Fuels Americas, Inc, in connection with the acquisition of a company by that name. The Company assumed its present name in March 2015, in connection with its commencement of operations in the legal cannabis market in Oregon.</span></p> <p style="margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has four subsidiaries: Marijuana Holdings Americas, Inc., a Florida corporation (“MJAI”), which is majority-owned and was formed on March 27, 2014 to maintain ownership of the Company’s Oregon based cannabis operations, 34225 Kowitz Road, LLC, a wholly-owned Oregon limited liability company which held ownership of the Company’s 26 acre property in Lebanon, Oregon (inactive since Feb 28, 2023 when the subject property was sold), Kaya Brand International, Inc., a Florida Corporation (“KBI”) which is majority-owned and was formed on October 14, 2019 to expand the business overseas (active) and Fifth Dimension Therapeutics, Inc., a Florida corporation which is majority owned (“FDT ”) and was formed on December 13, 2022 to develop and maintain ownership of the Company’s planned Psychedelic Treatment Centers offering psilocybin treatments.</span></p> <p style="margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">MJAI Oregon 1 LLC is the entity that holds the licenses for the Company’s retail store operations. MJAI Oregon 5 LLC is the entity that held the license application for the Company’s 26 acre farm property in Lebanon Oregon (property sold 2/28/23, inactive since that date).</span></p> <p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">KBI is the entity that holds controlling ownership interests in Kaya Farms Greece, S.A. (a Greek corporation) and Kaya Shalvah (“Kaya Farms Israel”, an Israeli corporation). These two entities were formed to facilitate expansion of the Company’s business in Greece and Israel respectively.</span></p> <p style="margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fifth Dimension Therapeutics, Inc. (FDT) is the entity that was formed to hold interests in psychedelic treatment facilities, with operations initially targeted for Oregon where FDT holds a 49% stake in FDT Oregon 1, LLC (“FDT1”, an Oregon limited liability company) and the Company has an irrevocable option to acquire the remaining 51% stake in FDT1 after the sunsetting in January 1, 2025 of Oregon’s residency requirements for majority ownership in entities that hold OHA issued psilocybin licenses. On September 5, 2024, the Company issued 1,000,000 shares of common stock to FDT Oregon 1 LLC owners who are also the Company’s related party to pursuant to acquire the remaining 51% equity interest of FDT Oregon 1 LLC after January 1, 2025 per the agreement.</span></p> <p style="margin: 0; text-align: justify"></p> <p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Nature of the Business</b> </span></p> <p style="margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In January 2014, KAYS incorporated MJAI, a wholly owned subsidiary, to focus on opportunities in the legal recreational and medical marijuana in the United States.</span></p> <p style="margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On July 3, 2014 opened its first Kaya Shack™ MMD in Portland, Oregon. Between April of 2014 and December 31, 2023, KAYS owned and operated four (4 ) Kaya Shack™ retail cannabis medical and recreational dispensaries, three (3) Medical Marijuana Grow sites licensed by the OHA and two (2) Recreational Marijuana grow sites licensed by the OLCC (all in Oregon). The statuses of these operations are as follows: </span></p> <p style="margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The first Kaya Shack™ (Kaya Shack™ Store 1) opened in 2014 in Portland, Oregon at the same address as an Oregon Liquor and Cannabis Commission (OLCC) licensed medical and recreational marijuana retailer. On March 11, 2024, the Company notified the Oregon Liquor Control Commission (the “OLCC”) that we were temporarily closing this location. The Company is currently evaluating redeploying this remaining dispensary license to serve as a delivery hub for Portland residents, tourists and The Sacred Mushroom™ guests, among others.</span></p> <p style="margin: 0 0 0 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kaya Shack™ Store 2 was closed in December, 2022 as part of a sale and surrender agreement that the Company entered into with the OLCC to resolve an Administrative Action filed by the OLCC (as previously disclosed in the Company’s Annual Report on form 10-K for the period ending December 31, 2021 filed on April 18, 2022 and in the Company’s Quarterly report for the period ending March 31, 2022 filed on May 16, 2022). Per the terms of the agreement the Company agreed to either enter into a purchase and sale agreement for its retail license in South Salem by February 1, 2023 (the renewal date) or surrender the license. On April 21, 2023 the Company concluded the sale of Store 2 for $210,000, less a 6% closing commission and minor closing expenses. After these expenses and paying $75,000 to resolve three non-performing store leases in South Oregon, the Company netted $118,900.</span><span style="font-size: 8pt"> </span></p> <p style="margin: 0; text-align: justify"></p> <p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="margin: 0 0 0 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kaya Shack™ Store 3 and Kaya Shack™ Store 4 were both closed due to consolidation moves by the Company in 2020 and 2021, respectively, and the Company let the licenses lapse. </span></p> <p style="margin: 0 0 0 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In August of 2017, the Company purchased a 26-acre parcel in Lebanon, Linn County, Oregon for $510,000 on which we intended to construct a Greenhouse Grow and Production Facility (the “<b>Property</b>”) and filed for OLCC licensure. In August of 2022, the Company entered into an agreement (the “<b>CVC Agreement</b>”) with CVC International, Inc. (“<b>CVC</b>”), an institutional investor who holds certain of the Company’s Convertible Promissory Notes (the “<b>Notes</b>”), one of which was secured by a $500,000 mortgage on the Property. CVC released its lien on the Property to enable the Company to sell the Property and utilize the proceeds therefrom for the benefit of the Company and its shareholders, without having to repay CVC the $500,000 Note held by CVC. Additionally, CVC agreed to advance certain sums against the sale of the Property (“<b>Advances</b>”), which amounted to $270,000 pending the sale of the Property. On February 28, 2023 we sold the Property for a price of $769,500, less commissions and customary closing costs. The net proceeds of the sale were used to repay the advances plus interest (including an additional $100,000 borrowed from another lender interest) and the Company realized net proceeds of approximately $302,000,000. The land is reflected on the balance sheet as assets held for sale for the year ended December 31, 2022 at a value of $516,076. The land was sold in 2023.</span><span style="font-size: 8pt"> </span></p> <p style="margin: 0 0 0 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On September 26, 2019, the Company formed the majority owned subsidiary Kaya Brands International, Inc. (“KBI”) to serve as the Company’s vehicle for expansion into worldwide cannabis markets. Between September of 2019 and March 31, 2024 KBI has formed majority-owned subsidiaries in both Greece and Israel and its local operating subsidiaries have acquired interests in various licenses and entities.</span></p> <p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On December 13, 2022 the Company formed Fifth Dimension Therapeutics <span style="color: #444444; background-color: white">™ </span>(“FDT”, a Florida Corporation) to seek to provide psychedelic services to sufferers of treatment resistant mental health diseases such as depression, PTSD and other mental health disorders. On January 3, 2023 the Oregon Health Authority (the “OHA”) began to accept license applications, allowing each entity to own and operate one (1) Psilocybin manufacturing and processing facility for the production of Psilocybin Mushrooms and derived therapeutics (“Psilocybins”), and up to five (5) Psilocybin Facilitation Centers where clients would go to ingest Psilocybins and experience effects under the supervision of State Licensed Facilitators.</span></p> <p style="margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On January 25, 2023 the Company confirmed that attorney Glenn E.J. Murphy was welcomed as a founding member to the FDT Board of Directors. Glenn will assist FDT with introductions to pharmaceutical companies seeking data and access to psychedelic patients, as well as advising on the development of intellectual property, structure of potential joint ventures, funding opportunities, acquisitions, and other related endeavors. Glenn has twenty-five years of private and corporate practice, including ten years in-house with the Henkel Group and more than fifteen years in private practice, Glenn's experience has touched on most every aspect of intellectual property practice.</span></p> <p style="margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 13, 2023, Bryan Arnold (one of KAYS Vice Presidents and its longest serving Oregon Employee) completed his OHA Certified Psilocybin Education through the Changra Institute and became one of the first eighteen graduates to obtain Psilocybin Facilitator certification in the State of Oregon. Bryan’s Facilitation License application has been approved by the OHA, and he now may oversee up to five (5) Psilocybin Treatment Facilities and up to one (1) Psilocybin Production Facility. Additionally, the Company expects to enroll additional potential licensee candidates within the coming months to bolster its ranks of OHA Licensed Psilocybin Facilitators as it moves forward with plans to open its first Psilocybin Clinic, subject to completion of financing and regulatory approvals.</span></p> <p style="margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On November 14, 2023 the Company filed a license application with the Oregon Department of Health (the “OHA”) for the licensure of The Sacred Mushroom™, an approximately 11,000 square foot psilocybin treatment center located in Portland, Oregon which would serve as the Company’s flagship psilocybin facility.</span></p> <p style="margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 6, 2024, the OHA completed its Psilocybin Service Center License Inspection and itemized three (3) facility structural/layout items that they wanted addressed/modified prior to issuing the facility license. On May 7, 2024, the Company had been awarded its license by the Oregon Health Authority to operate its Portland, Oregon psilocybin treatment center, The Sacred Mushroom. On July 2, 2024, the Company announced </span><span style="font-size: 8pt"> </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">that its licensed psilocybin treatment center, The Sacred Mushroom would open for business on July 5, 2024 and immediately commencing begin administering psilocybin treatments to eligible guests.</span></p> <p style="margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="margin: 0; text-align: justify"></p> <p style="margin: 0; text-align: justify"></p> <p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>
	KAYS	Incurred Net Loss IncurredNetLoss	3139691	usd
	KAYS	Incurred Net Loss IncurredNetLoss	1368016	usd
CY2024Q3	KAYS	Working Capital WorkingCapital	8982011	usd
	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p id="xdx_848_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zOXCmc1Bhk0i" style="margin: 0 0 6pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86A_zBW5ArqB2y0l">Reclassifications</span></b></span></p> <p style="margin: 0 0 6pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain prior period amounts have been reclassified to conform to the current period presentation.</span></p>
	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_844_eus-gaap--UseOfEstimates_z3Ze8RzFFrpe" style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_863_zD6iHrYSrAm4">Use of Estimates</span></b></span></p> <p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes.</span></p> <p style="margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Such estimates and assumptions impact both assets and liabilities, including but not limited to: net realizable value of accounts receivable and inventory, estimated useful lives and potential impairment of property and equipment, the valuation of intangible assets, estimate of fair value of share based payments and derivative liabilities, estimates of fair value of warrants issued and recorded as debt discount, estimates of tax liabilities and estimates of the probability and potential magnitude of contingent liabilities.</span></p> <p style="margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate could change in the near term due to one or more future non-conforming events. Accordingly, actual results could differ significantly from estimates.</span></p> <p style="margin: 0; text-align: justify"></p> <p style="margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_840_eus-gaap--ConcentrationRiskCreditRisk_zw9SUdz9nhL3" style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_862_z1NgE7ImuQAd">Risks and Uncertainties</span></b></span></p> <p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s operations are subject to risk and uncertainties including financial, operational, regulatory and other risks including the potential risk of business failure. </span></p> <p style="margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has experienced, and in the future expects to continue to experience, variability in its sales and earnings. The factors expected to contribute to this variability include, among others, (i) the uncertainty associated with the commercialization and ultimate success of the product, (ii) competition inherent at other locations where product is expected to be sold (iii) general economic conditions and (iv) the related volatility of prices pertaining to the cost of sales.</span></p> <p style="margin: 0 0 6pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>
CY2024Q3	us-gaap	Inventory Finished Goods InventoryFinishedGoods	240	usd
CY2023Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	9259	usd
CY2024Q3	us-gaap	Inventory Adjustments InventoryAdjustments	0	usd
CY2023Q4	us-gaap	Inventory Adjustments InventoryAdjustments	0	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	23327	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	93910	usd
	us-gaap	Derivatives Embedded Derivatives DerivativesEmbeddedDerivatives	<p id="xdx_845_eus-gaap--DerivativesEmbeddedDerivatives_zl3OtCG5NDW9" style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_869_zHvHKbQ2VEog">Embedded Conversion Features</span></b></span></p> <p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company evaluates embedded conversion features within convertible debt under ASC 815 “Derivatives and Hedging” to determine whether the embedded conversion feature(s) should be bifurcated from the host instrument and accounted for as a derivative at fair value with changes in fair value recorded in earnings. </span><span style="font-size: 8pt"> </span></p> <p style="margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2024Q3	us-gaap	Capitalized Computer Software Net CapitalizedComputerSoftwareNet	30713	usd
CY2023Q4	us-gaap	Capitalized Computer Software Net CapitalizedComputerSoftwareNet	30713	usd
CY2024Q3	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	56978	usd
CY2023Q4	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	56978	usd
CY2024Q3	us-gaap	Property Plant And Equipment Other PropertyPlantAndEquipmentOther	25000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Other PropertyPlantAndEquipmentOther	25000	usd
CY2024Q3	us-gaap	Land Land	17703	usd
CY2023Q4	us-gaap	Land Land	17703	usd
CY2024Q3	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	51070	usd
CY2023Q4	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	32304	usd
CY2024Q3	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	55067	usd
CY2023Q4	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	55067	usd
CY2024Q3	us-gaap	Timber And Timberlands TimberAndTimberlands	24000	usd
CY2023Q4	us-gaap	Timber And Timberlands TimberAndTimberlands	24000	usd
CY2024Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	260531	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	241765	usd
CY2024Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	220270	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	216890	usd
CY2024Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	40261	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	24875	usd
	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	3380	usd
	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	13611	usd
CY2024Q3	us-gaap	Receivables Net Current ReceivablesNetCurrent	11137	usd
CY2023Q4	us-gaap	Receivables Net Current ReceivablesNetCurrent	11047	usd
CY2024Q3	us-gaap	Time Deposits Noncurrent TimeDepositsNoncurrent	12925	usd
CY2023Q4	us-gaap	Time Deposits Noncurrent TimeDepositsNoncurrent	23941	usd
CY2024Q3	us-gaap	Deposits Assets DepositsAssets	5491	usd
CY2023Q4	us-gaap	Deposits Assets DepositsAssets	5491	usd
CY2024Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	29553	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	40479	usd
	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	90	usd
CY2024Q3	us-gaap	Accounts Payable Current And Noncurrent AccountsPayableCurrentAndNoncurrent	598381	usd
CY2023Q4	us-gaap	Accounts Payable Current And Noncurrent AccountsPayableCurrentAndNoncurrent	561551	usd
CY2024Q3	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	47719	usd
CY2023Q4	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	27534	usd
CY2024Q3	us-gaap	Accounts Payable And Accrued Liabilities Current And Noncurrent AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent	646100	usd
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Current And Noncurrent AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent	589085	usd
CY2024Q3	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	8504652	usd
CY2023Q4	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	7807152	usd
CY2024Q3	KAYS	Convertible Notes Payable Long Term Net Of Discounts ConvertibleNotesPayableLongTermNetOfDiscounts	280700	usd
CY2023Q4	KAYS	Convertible Notes Payable Long Term Net Of Discounts ConvertibleNotesPayableLongTermNetOfDiscounts	387819	usd
CY2024Q3	KAYS	Convertible Debt Net Of Discounts ConvertibleDebtNetOfDiscounts	8223952	usd
CY2023Q4	KAYS	Convertible Debt Net Of Discounts ConvertibleDebtNetOfDiscounts	7419333	usd
CY2024Q3	KAYS	Convertible Debt Net Of Discounts Current ConvertibleDebtNetOfDiscountsCurrent	135000	usd
CY2023Q4	KAYS	Convertible Debt Net Of Discounts Current ConvertibleDebtNetOfDiscountsCurrent	240288	usd
CY2024Q3	us-gaap	Convertible Debt ConvertibleDebt	8088952	usd
CY2023Q4	us-gaap	Convertible Debt ConvertibleDebt	7179045	usd
CY2024Q3	us-gaap	Notes Payable Current NotesPayableCurrent	9312	usd
CY2023Q4	us-gaap	Notes Payable Current NotesPayableCurrent	124312	usd
CY2024Q3	KAYS	Noncurrent Convertible Notes NoncurrentConvertibleNotes	500000	usd
CY2023Q4	KAYS	Noncurrent Convertible Notes NoncurrentConvertibleNotes	500000	usd
CY2024Q3	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	509312	usd
CY2023Q4	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	624312	usd
CY2024Q3	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	509312	usd
CY2023Q4	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	624312	usd
CY2024Q3	us-gaap	Loans Payable LoansPayable	250000	usd
CY2023Q4	us-gaap	Loans Payable LoansPayable	250000	usd
CY2024Q3	KAYS	Trading Price TradingPrice	0.0406
CY2024Q3	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	3900734	usd
CY2023Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	2752321	usd
CY2023Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	2752321	usd
	KAYS	Change In Derivative Value ChangeInDerivativeValue	759620	usd
	KAYS	Initial Derivative InitialDerivative	388793	usd
CY2024Q3	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	3900734	usd
CY2024Q3	us-gaap	Deferred Compensation Equity DeferredCompensationEquity	25000	usd
CY2024Q1	us-gaap	Compensated Absences Liability CompensatedAbsencesLiability	500000	usd
CY2024Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	83155	usd
CY2024Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	83155	usd
	us-gaap	Payments For Rent PaymentsForRent	235463	usd
	us-gaap	Payments For Rent PaymentsForRent	65778	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	32283	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	53805	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	86088	usd
CY2024Q3	KAYS	Lessee Operating Leases Liability Undiscounted Excess Amount LesseeOperatingLeasesLiabilityUndiscountedExcessAmount	2933	usd
CY2024Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	83155	usd
CY2024Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	83155	usd
CY2024Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P8Y
CY2024Q1	us-gaap	Loss Contingency Damages Awarded Value LossContingencyDamagesAwardedValue	12149.00	usd
CY2024Q1	us-gaap	Loss Contingency Accrual Insurance Related Assessment Discount Rate LossContingencyAccrualInsuranceRelatedAssessmentDiscountRate	0.09	pure

Files In Submission

Name	View Source	Status
0001903596-24-000689-index-headers.html	Edgar Link	pending
0001903596-24-000689-index.html	Edgar Link	pending
0001903596-24-000689.txt	Edgar Link	pending
0001903596-24-000689-xbrl.zip	Edgar Link	pending
ex31_1.htm	Edgar Link	pending
ex32_1.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
image_001.jpg	Edgar Link	pending
image_002.jpg	Edgar Link	pending
image_003.jpg	Edgar Link	pending
image_004.jpg	Edgar Link	pending
image_005.jpg	Edgar Link	pending
image_006.jpg	Edgar Link	pending
image_007.jpg	Edgar Link	pending
image_008.jpg	Edgar Link	pending
image_009.jpg	Edgar Link	pending
image_010.jpg	Edgar Link	pending
image_011.jpg	Edgar Link	pending
image_012.jpg	Edgar Link	pending
image_013.jpg	Edgar Link	pending
image_014.jpg	Edgar Link	pending
image_015.jpg	Edgar Link	pending
image_016.jpg	Edgar Link	pending
image_017.jpg	Edgar Link	pending
image_018.jpg	Edgar Link	pending
image_019.jpg	Edgar Link	pending
image_020.jpg	Edgar Link	pending
image_021.jpg	Edgar Link	pending
image_022.jpg	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
image_023.jpg	Edgar Link	pending
image_024.jpg	Edgar Link	pending
image_025.jpg	Edgar Link	pending
image_026.jpg	Edgar Link	pending
image_027.jpg	Edgar Link	pending
image_028.jpg	Edgar Link	pending
image_029.jpg	Edgar Link	pending
image_030.jpg	Edgar Link	pending
image_031.jpg	Edgar Link	pending
image_032.jpg	Edgar Link	pending
kays-20240930.xsd	Edgar Link	pending
kays_10q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
kays-20240930_cal.xml	Edgar Link	unprocessable
kays-20240930_def.xml	Edgar Link	unprocessable
kays-20240930_lab.xml	Edgar Link	unprocessable
kays-20240930_pre.xml	Edgar Link	unprocessable
kays_10q_htm.xml	Edgar Link	completed
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$KAYS
Kaya Holdings, Inc. Stock $kays

2024 Q4 Form 10-Q Financial Statement

#000190359624000689 Filed on November 22, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$KAYS Kaya Holdings, Inc. Stock $kays

2024 Q4 Form 10-Q Financial Statement

#000190359624000689 Filed on November 22, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$KAYS
Kaya Holdings, Inc. Stock $kays